Trial · NCT00970359
Reacquisition of Radioactive Iodine (RAI) Uptake of RAI-Refractory Metastatic Thyroid Cancers by Pretreatment With the Selective MEK Inhibitor AZD6244
NCT00970359, Not applicable, Completed, Memorial Sloan Kettering Cancer Center; results first posted 2017-04-12
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Reacquisition of Radioactive Iodine (RAI) Uptake of RAI-Refractory Metastatic Thyroid Cancers by Pretreatment With the Selective MEK Inhibitor AZD6244. Trials, record NCT00970359. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00970359
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Reacquisition of Radioactive Iodine (RAI) Uptake of RAI-Refractory Metastatic Thyroid Cancers by Pretreatment With the Selective MEK Inhibitor AZD6244
- NCT number
- NCT00970359
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 24 participants, actual
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Conditions
- Thyroid Cancer
- Interventions
- AZD6244
- First posted
- 2009-09-02
- Last updated
- 2017-04-12
- Results first posted
- 2017-04-12
Source ClinicalTrials.gov
Registered outcomes3
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Patients Whose Tumor(s) Acquire an Increased Propensity for Iodine Uptake as Detected on Iodine-124 Positron Emission Tomography Scan | 2 years | |
| Primary | Tumor Response Defined as Either a Complete Response or Partial Response | 6 months | as defined by the RECIST v1.1 criteria Descriptive statistics will be used to summarize the data. |
| Secondary | Change From Baseline in Serum Thyroglobulin Levels After Treatment With 131I | At 2 months and 6 months after Radioiodine administration | Will perform a Wilcoxon signed rank test for paired samples to compare the serum thyroglobulin level before and after 131I treatment in the subset of patients treated with 131I following AZD6244. |
Source ClinicalTrials.gov
Outcomes3
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Number of Patients Whose Tumor(s) Acquire an Increased Propensity for Iodine Uptake as Detected on Iodine-124 Positron Emission Tomography Scan | 2 years | participants | NUMBER | |
| PRIMARY | Tumor Response Defined as Either a Complete Response or Partial Response | 6 months | Only patients treated with radioiodine. | participants | NUMBER |
| SECONDARY | Change From Baseline in Serum Thyroglobulin Levels After Treatment With 131I | At 2 months and 6 months after Radioiodine administration | Only patients treated with Radioiodine. | percentage of reduction of levels | MEAN |
Source ClinicalTrials.gov
Results by group6
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Patients Whose Tumor(s) Acquire an Increased Propensity for Iodine Uptake as Detected on Iodine-124 Positron Emission Tomography Scan | AZD6244 | New and/or increase | 12 | participants | |
| Number of Patients Whose Tumor(s) Acquire an Increased Propensity for Iodine Uptake as Detected on Iodine-124 Positron Emission Tomography Scan | AZD6244 | Remained the same or less | 8 | participants | |
| Tumor Response Defined as Either a Complete Response or Partial Response | AZD6244 | Partial Response | 5 | participants | |
| Tumor Response Defined as Either a Complete Response or Partial Response | AZD6244 | Stable Disease | 3 | participants | |
| Change From Baseline in Serum Thyroglobulin Levels After Treatment With 131I | AZD6244 | at 2 months | 89 | Full Range 74.4 to 99.9 | percentage of reduction of levels |
| Change From Baseline in Serum Thyroglobulin Levels After Treatment With 131I | AZD6244 | at 6 months | 80 | Full Range 5.1 to 100 | percentage of reduction of levels |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | AZD6244 | 24 | |
| Overall Study | COMPLETED | AZD6244 | 20 | |
| Overall Study | NOT COMPLETED | AZD6244 | 4 |
Source ClinicalTrials.gov
Adverse events12
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Blood bilirubin increased | Investigations | AZD6244 | 1 | 24 | 2 |
| other | Creatinine increased | Investigations | AZD6244 | 1 | 24 | 2 |
| other | Hyperglycemia | Metabolism and nutrition disorders | AZD6244 | 2 | 24 | 2 |
| other | Hyperkalemia | Metabolism and nutrition disorders | AZD6244 | 1 | 24 | 1 |
| other | Hypertension | Vascular disorders | AZD6244 | 5 | 24 | 6 |
| other | Hypocalcemia | Metabolism and nutrition disorders | AZD6244 | 2 | 24 | 3 |
| other | Pain in extremity | Musculoskeletal and connective tissue disorders | AZD6244 | 1 | 24 | 1 |
| other | Palpitations | Cardiac disorders | AZD6244 | 1 | 24 | 1 |
| other | Rash acneiform | Skin and subcutaneous tissue disorders | AZD6244 | 3 | 24 | 4 |
| other | Rash maculo-papular | Skin and subcutaneous tissue disorders | AZD6244 | 4 | 24 | 4 |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 adverse eventsAdverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | AZD6244 | ||
| Total, other adverse events | AZD6244 | 11 | 24 |
| Total, serious adverse events | AZD6244 | 2 | 24 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 23406027 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00970359
GET https://conductscience.org/api/trials/v1/NCT00970359/registered